Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Istiratumab in metastatic pancreatic cancer
NCT02399137Phase 2Completed
- Sponsor
- Merrimack Pharmaceuticals
- Start
- May 2015
- Primary completion
- Aug 2018
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of istiratumab in pancreatic cancer (PC), sponsored by Merrimack Pharmaceuticals. Started May 2015; status: completed.
02
Drugs
istiratumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02399137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02399137.